表紙
市場調査レポート

抗癌キナーゼ阻害剤:世界市場およびパイプラインの分析

Global Cancer Kinase Inhibitors Market & Pipeline Insight

発行 KuicK Research 商品コード 316010
出版日 ページ情報 英文 1500 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
抗癌キナーゼ阻害剤:世界市場およびパイプラインの分析 Global Cancer Kinase Inhibitors Market & Pipeline Insight
出版日: 2014年10月01日 ページ情報: 英文 1500 Pages
概要

キナーゼ阻害剤の作用については、過去20年に渡って研究が続けられており、癌治療への応用も徐々に拡大しています。これらの薬剤が市場でますます多く利用可能になっており、製薬事業者による新しいコンビネーションアプローチの開発を可能にしています。

当レポートでは、抗癌キナーゼ阻害剤の市場とパイプラインの動向について調査し、キナーゼ阻害剤の種類と概要、作用機序、キナーゼ阻害抗癌剤のニーズ、キナーゼ阻害剤の市場規模の推移と予測、地域的内訳、パイプラインの状況、主要事業者のプロファイルなどをまとめています。

第1章 キナーゼ阻害剤:イントロダクション

  • 癌増殖抑制剤
  • 癌増殖抑制剤の各種タイプ
  • チロシンキナーゼ阻害剤

第2章 キナーゼ阻害剤の分類

  • I型キナーゼ阻害剤
  • II型キナーゼ阻害剤
  • III型キナーゼ阻害剤
  • IV型キナーゼ阻害剤または基質指向阻害剤
  • 共有結合阻害剤

第3章 キナーゼ阻害剤の作用機序

  • チロシンキナーゼの生化学的作用機序
  • チロシンキナーゼの発癌作用
    • 突然変異による発癌
    • BCR-ABLとヒト白血病
    • TEL-ABLとヒト白血病
    • 自己分泌(autocrine)・傍分泌(paracrine)ループ
    • 自己分泌(autocrine)・傍分泌(paracrine)ループにおけるEGFR
    • 自己分泌(autocrine)・傍分泌(paracrine)ループにおけるPDGFR
    • 自己分泌(autocrine)ループにおけるインスリン様成長因子受容体
  • 抗癌剤の標的としてのチロシンキナーゼ

第4章 キナーゼ阻害抗癌剤のニーズ

第5章 キナーゼ阻害抗癌剤の市場概要

  • 現在の市場シナリオ
  • 抗癌キナーゼ阻害剤のパイプラインの概要

第6章 キナーゼ阻害抗癌剤の市場力学

  • 有利となるパラメーター
  • 成長抑制因子

第7章 キナーゼ阻害抗癌剤市場の将来の展望

第8章 キナーゼ阻害抗癌剤のパイプライン:相・適応症・企業・国別

  • 相:不明
  • 相:研究
  • 相:前臨床
  • 相:臨床
  • 第I相
  • 第I相/II
  • 第II相
  • 第II/III相
  • 第III相
  • 承認前
  • 承認済み

第9章 上市済みキナーゼ阻害抗癌剤:適応症・企業・国別

第10章 延期・中止のパイプライン薬

  • 進捗報告なし
  • 中止
  • 延期

第11章 競合環境

  • Amgen
  • AstraZeneca
  • AVEO Pharmaceuticals
  • Bayer HealthCare Pharmaceuticals
  • Boehringer Ingelheim
  • Deciphera Pharmaceuticals
  • Genentech
  • GlaxoSmithKline
  • Incyte Corporation
  • Novartis
  • Pfizer
  • 武田薬品工業

図表一覧

目次

The recent years have witnessed the emergence of kinase inhibitors, which have the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past two decades, the researchers have increased their learning about the functioning of these inhibitors, which has led to the achievement of significant milestones of development during this period. The use of inhibitors for treating cancer is gradually increasing. The rising market availability of these agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body's acceptance of inhibitors so as to develop more efficient drugs.

The field of cancer is growing mainly because of the globally aging population, increasing rates of obesity and rising smoking rates across all regions. This opens the door of opportunities for the drug makers globally because the kinase inhibitors is highly competitive and is currently in growing stages, thus offering significant areas of unmet medical need. The future years are likely to witness significantly increased levels of activity in the development of these drugs.

Additionally, with the industry undergoing the period of "patent cliff", the pharma companies are rapidly working towards filling up their exhausting pipelines with alternative and innovative drugs. Kinase inhibitors fit these spaces most appropriately, which is likely to drive future growth and improve the survival rates of cancer patients.

A significant amount of research is being carried out currently to improve the level of potency of the already developed kinase inhibitors. Consequently, a relatively new approach has been indentified in which the precision of targeting molecules would be combined with the proved killing power of radiation or cytotoxic chemotherapy which is referred to as payload to precise molecular carriers. However, still a lot of work needs to be done in this arena.

It is expected that during the next decade, with the discovery and introduction of new tumor-specific proteins, newer kinase inhibitor drugs targets would be successfully identified for regulating tumor cell growth. Additionally, the innovations and dynamics in inhibitors would also allow for more efficient cytotoxic kinase inhibitor drug targeting or lead to more efficient activation of host effector mechanisms which tend to lead to better therapeutic targets.

"Global Cancer Kinase Inhibitors Market & Pipeline Insight" Report Highlight:

  • Classification & Mechanism of Kinase Inhibitors
  • Cancer Kinase Inhibitors Therapy Market Overview
  • Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country
  • Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country
  • Patent Analysis & Orphan Designation of Kinase Inhibitors
  • Cancer Kinase Inhibitors In Clinical Pipeline: 649 Drugs
  • Marketed Cancer Kinase Inhibitors: 35 Drugs

Table of Contents

1. Introduction to Kinase Inhibitors

  • 1.1 Cancer Growth Blockers
  • 1.2 Types of Cancer Growth Blockers
  • 1.3 Tyrosine Kinase Inhibitors

2. Kinase Inhibitors Classification

  • 2.1 Type I Kinase Inhibitors
  • 2.2 Type II Kinase Inhibitors
  • 2.3 Type III Kinase Inhibitors
  • 2.4 Type IV Kinase Inhibitors or Substrate Directed Inhibitors
  • 2.5 Covalent Inhibitors

3. Mechanisms of Kinase Inhibitors

  • 3.1 Biochemical Mechanism of Action of Tyrosine Kinase
  • 3.2 Oncogenic Activation of Tyrosine Kinase
    • 3.2.1 Activation by Mutation
    • 3.2.2 BCR-ABL and Human Leukemia
    • 3.2.3 TEL-ABL and Human Leukemia
    • 3.2.4 Autocrine-Paracrine Loops
    • 3.2.5 EGFR in Autocrine Paracrine Loops
    • 3.2.6 PDGFR in Autocrine Paracrine Loop
    • 3.2.7 Insulin like Growth Factor Receptors in Autocrine Growth Loop
  • 3.3 Tyrosine Kinases as Targets for Anticancer Agents

4. Need for Cancer Kinase Inhibitor Therapy

5. Cancer Kinase Inhibitors Therapy Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Cancer Kinase Inhibitors Pipeline Overview

6. Cancer Kinase Inhibitors Therapy Market Dynamics

  • 6.1 Favorable Parameters
  • 6.2 Growth Restraints

7. Cancer Kinase Inhibitors Therapy Market Future Outlook

8. Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country

  • 8.1 Phase: Unknown
  • 8.2 Phase: Research
  • 8.3 Phase: Preclinical
  • 8.4 Phase: Clinical
  • 8.5 Phase-I
  • 8.6 Phase-I/II
  • 8.7 Phase-II
  • 8.8 Phase-II/III
  • 8.9 Phase-III
  • 8.10 Preregistration
  • 8.11 Registered

9. Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country

10. Suspended & Discontinued in Cancer Kinase Inhibitors Therapy Pipeline

  • 10.1 No Development Reported
  • 10.2 Discontinued
  • 10.3 Suspended

11. Competitive Landscape

  • 11.1 Amgen
  • 11.2 AstraZeneca
  • 11.3 AVEO Pharmaceuticals
  • 11.4 Bayer HealthCare Pharmaceuticals
  • 11.5 Boehringer Ingelheim
  • 11.6 Deciphera Pharmaceuticals
  • 11.7 Genentech
  • 11.8 GlaxoSmithKline
  • 11.9 Incyte Corporation
  • 11.10 Novartis
  • 11.11 Pfizer
  • 11.12 Takeda
  • Figure 2-1: Kinase Inhibitors Classification
  • Figure 3-1: Mechanisms of Constitutive Activation of Kinase Inhibitors
  • Figure 5-1: Global Market for Kinase Inhibitors (US$ Billion), 2013-2020
  • Figure 5-2: Global Market for Cancer Kinase Inhibitors (US$ Billion), 2013-2020
  • Figure 5-3: Regional Break-Up for Kinase Inhibitors Market (%), 2013 & 2020
  • Figure 5-4: Cancer Kinase Inhibitors Pipeline by Phase (%), 2014
  • Figure 5-5: Cancer Kinase Inhibitors Pipeline by Phase (%), 2014
  • Figure 5-6: No Development Reported in Cancer Kinase Inhibitors Pipeline by Phase (%), 2014
  • Figure 5-7: No Development Reported in Cancer Kinase Inhibitors Pipeline by Phase (Number), 2014
  • Figure 5-8: Discontinued Cancer Kinase Inhibitors Pipeline by Phase (%), 2014
  • Figure 5-9: Discontinued Cancer Kinase Inhibitors Pipeline by Phase (Number), 2014
  • Figure 5-10: Suspended Cancer Kinase Inhibitors Pipeline by Phase (%), 2014
  • Figure 5-11: Suspended Cancer Kinase Inhibitors Pipeline by Phase (Number), 2014
  • Table 1-1: Drugs Targeting Kinase Inhibitors
  • Table 2-1: Comparison Between Different Types of Kinase Inhibitors
Back to Top